Novel Therapeutic Agents in Waldenström's Macroglobulinemia
- 1 March 2009
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 9 (1), 84-86
- https://doi.org/10.3816/clm.2009.n.022
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Targeting NF-κB in Waldenstrom macroglobulinemiaBlood, 2008
- Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemiaBlood, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Waldenström macroglobulinemiaBlood, 2007
- Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemiaBlood, 2007
- Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsBlood, 2006
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Diagnosis and Management of Waldenstrom's MacroglobulinemiaJournal of Clinical Oncology, 2005
- Waldenström macroglobulinaemiaThe Lancet Oncology, 2003
- Defining Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003